ReviewFrontiers in oncology2020

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses.

Hongjing Zang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.